Loading stock data…
Invivyd, Inc. (IVVD)
$0.61+0.00 (+0.36%)
Market ClosedLast close Jul 24
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Invivyd, Inc. in the Healthcare sector is trading at $0.61 with a market capitalization of $324M. Wall Street consensus targets $10.00 (3 analysts), implying a +1535.6% move over the next 12 months. The stock is currently near its 52-week low of $0.48, remaining 62.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1535.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.74M↓ | $17.21M↑ | $13.13M↑ | $11.79M↑ | $11.30M |
| Gross Profit | $12.71M↓ | $16.07M↑ | $12.04M↑ | $11.10M↑ | $10.47M |
| Operating Income | -$43.14M↓ | -$12.55M↓ | -$11.02M↑ | -$15.06M↑ | -$16.92M |
| Net Income | -$41.40M↓ | -$11.07M↓ | -$10.47M↑ | -$14.66M↑ | -$16.29M |
Peer Comparison
JNJUNHPFE
Fundamentals
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$324.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.22%
Volume
Today's trading volume
3.03M
Recent News
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
PEMGARDA’s emergency status will end on June 29, 2027, unless the company secures full FDA approval in the meantime.
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311
Invivyd Inc. (NASDAQ:IVVD) is one of the best growth stocks under $30 to buy now. On June 9, Invivyd dosed the first participants in its LIBERTY Phase 3 clinical trial, a study comparing the safety and tolerability of its monoclonal antibody candidate, VYD2311, against mRNA COVID-19 vaccines. The randomized, double-blind trial involves ~210 healthy adults […]
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability...
Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311
Invivyd (IVVD) dosed the first participants in the LIBERTY phase 3 clinical trial evaluating the saf
This Invivyd Insider Increased Their Holding In The Last Year
Looking at Invivyd, Inc.'s ( NASDAQ:IVVD ) insider transactions over the last year, we can see that insiders were net...